PHARMACEUTICAL COMPOSITION CONTAINING ANTIARRHYTHMIC DRUG WITH INCREASED DISSOLUTION PROPERTY IN ACIDIC MEDIA

• Main Authors: KIM, JEONG HOON, HAN, SANG DUG, JANG, SUN WOO, JUNG, SANG WON
• Format: Patent
• Language: English; Korean
• Published: 27.08.2012
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

PURPOSE: An arrhythmia treatment material is provided to maximize elution rate of main components in an acidic region, thereby improving lower bio-availability of salt or dronedaron in fast-state. CONSTITUTION: An arrhythmia treatment material is coprecipitate type dronedaron solid dispersion or solid liquid. The coprecipitate type dronedarone solid dispersion or the solid liquid contains a water soluble polymer and dronedarone or pharmaceutically allowable salt. The solid dispersion contains a water soluble polymer and dronedarone or pharmaceutically allowable salt. The dronedaron and the water soluble polimer are contained at a weight ratio of 1:0.2-1:5. The solid dispersion or the solid liquid additionally contains surfactant. A manufacturing method of the dronedarone contained solid dispersion or the solid liquid comprises the following steps: melting the dronedarone or the salt which is pharmaceutically allowable and the water soluble polymer in an organic solvent; and removing the organic solvent by freeze-drying, figure forming drying, compression drying or spray drying. The organic solvent is acetone, ethyl acetate, methanol, ethanol or isopropyl alcohol. The dronedarone contained solid dispersion or the solid liquid is formed into acida, granule, capsule or tablet.